SCHEMBL6489335

SCHEMBL6489335

CCOC(=O)Cc1c(O)nc2ccc(OC)c(OC)c2c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.46
POLB P06746 1/20 0.46
HTT P42858 1/20 0.46
PDE3B Q13370 2/20 0.45
PDE3A Q14432 2/20 0.45
MAPT P10636 5/20 0.41
GAA P10253 2/20 0.41
ALDH1A1 P00352 6/20 0.38
HPGD P15428 3/20 0.38
TSHR P16473 2/20 0.38
RAB9A P51151 1/20 0.38
KDM4E B2RXH2 4/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
GLA P06280 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPK1 P28482 2/20 0.37
USP2 O75604 1/20 0.37
LMNA P02545 1/20 0.37
AHR P35869 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7056217 0.82 ALDH1A1 (0.42) HSD17B10POLBHTTMAPTGAA
SCHEMBL7061647 0.82 MAPK1 (0.37) HSD17B10HTTMAPTGAAALDH1A1
SCHEMBL7055139 0.81 ALDH1A1 (0.41) POLBMAPTGAAALDH1A1TSHR
SCHEMBL7058670 0.81 MAPK1 (0.36) HSD17B10MAPTGAAALDH1A1HPGD
SCHEMBL7056212 0.79 KDM4E (0.41) HSD17B10POLBHTTMAPTGAA
SCHEMBL7059106 0.78 MAPK1 (0.34) HSD17B10POLBHTTMAPTGAA
SCHEMBL7057147 0.78 KDM4E (0.39) HSD17B10HTTMAPTALDH1A1HPGD
SCHEMBL6499160 0.78 HSD17B10 (0.44) HSD17B10HTTMAPTALDH1A1HPGD
SCHEMBL7061260 0.77 KDM4E (0.40) HSD17B10POLBHTTMAPTGAA
SCHEMBL6500221 0.77 ABCB1 (0.50) POLBPDE3BPDE3AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6908932-B2 Cancer therapy ICONIX PHARMACEUTICALS, INC. (US) 2005-06-21 US disclosed
US-20030149074-A1 Modulators of phosphoinositide 3-kinase ENTELOS HOLDING CORP. 2003-08-07 US disclosed
WO-2003035618-A2 MODULATORS OF PHOSPHOINOSITIDE 3-KINASE ICONIX PHARMACEUTICALS, INC. (US) 2003-05-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149074-A1 Modulators of phosphoinositide 3-kinase PIK3R1, PIK3R3, PIK3R4 HSD17B10 894/4885POLB 3871/4885HTT 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.